Substitute for form 1449/PTO (Revised 07/2007)	Complete if Known	
	Application Number	10/599,448
	Filing Date	03/08/2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Pascal Drevet
	Art Unit	1648
(Use as many sheets as necessary)	Examiner Name	Stuart Snyder
Sheet 1 of I	Attorney Docket Number	033339/317269

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	I	L. STEINAA, A.M. SERENSEN, J.O. NIELSEN, and J.-E.S. HANSEN; "Antibody to HIV-1 Tat protein inhibits the replication of virus in culture"; ARCHIVES OF VIROLOGY; SPRINGER-VERLAG 1994, PRINTED IN AUSTRIA; Vol. 139; pages 263-271.	
	2	TODD M. ALLEN, ET AL.; "Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia"; NATURE; Vol. 147; September 21, 2000; pages 386-390.	
	3	ALAIN LECOQ, ET AL.; "Increasing the humoral immunogenic properties of the HIV-I Tat protein using a ligand-stabilizing strategy; VACCINE; 2008; Vol. 26; Pages 2615-2626.	
	4	SABRINA TURBANT, ET AL.; "Cynomolgus macaques immunized with two HIV-I Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of ThI/Th2 response differing from that in mice; VACCINE; 2009; doi:I0.I016/j.vaccine.2009.06.083.	
	5	"Effect of a heparin fragment (Hep6000) on HIV VPR and Nef Immunogenicity".	

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.